Department of Anesthesiology and Intensive Care Medicine, Campus Charité Mitte and Campus Virchow - Klinikum, Charité- Universitätsmedizin
Berlin, 13353, Germany
NCT Number: NCT02044575
Despite large efforts trying to improve diagnostic and therapy of sepsis have been made over the last decade (e.g. initiation of the Surviving Sepsis Campaign, defining evidence based sepsis therapy bundles) the mortality of septic shock remains high and causes high socioeconomical burden of disease.
The purpose of this pilot study is to evaluate the design and conduct of a projected full scale clinical trial.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Berlin, 13353, Germany
A functional clock is required for induction of several proinflammatory genes, not shown in septic patient settings, yet.
Clock genes are involved in modulating the activity of several transcription factors that are important regulators of immune functions (e.g. HIF1-α, STAT1, STAT3, and NF-κB) (Bellet MM et al., 2013).
Furthermore, polymorphisms such as rs7221412, a common polymorphism near period homolog 1 (PER1), was associated with the timing of activity rhythms and also showed a suggestive time-dependent relationship with both cerebral cortex and monocytes PER1 expression and an association with time of death (Lim ASP et al., 2012).
This explorative project is a pilot study. First data are generated for the assessment of the circadian system in patients with septic shock.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: These parameters are measured during intensive care unit stay, for a maximum of 3 days
Circadian regulation by expression of clock genes
Time frame: They are followed up until the end of intensive care unit stay - or, for a maximum of 28 days
Time frame: Participants will be followed for the duration of intensive care stay, an expected average of 4 weeks
Time frame: Participants will be followed for the duration of intensive care stay, an expected average of 5 weeks
Time frame: They are measured until the end of intensive care unit stay - or, for a maximum of 28 days.
Time frame: They are measured until the end of intensive care unit stay - or, for a maximum of 28 days.
Time frame: They are measured until the end of intensive care unit stay - or, for a maximum of 28 days.
Time frame: 6 months after intensive care unit discharge
Time frame: Light frequencies are measured until the end of intensive care unit stay - or, for a maximum of 28 days
Time frame: Light levels are measured until the end of intensive care unit stay - or, for a maximum of 28 days
Time frame: This parameter is measured in ng/ml during intensive care unit stay, for a maximum of 3 days
Time frame: This parameter is measured in pg/ml during intensive care unit stay, for a maximum of 3 days
Time frame: Up to 3 and 6 months
Quality of life is measured by SF-36 questionnaire
Time frame: Up to 3 and 6 months
Cognitive function is measured by Repeatable Battery for the Assessment of Neuropsychological Status
Time frame: These parameters are measured during intensive care unit stay, for a maximum of 3 days
Ncounter neuroinflammation and micro rna panel are analysed
Time frame: This parameter is measured at the beginning of the investigation
Nagalase Enzyme activity is expressed in nmol/min per Milliliter. Analysis is evaluated with the perioperative Nagalase results of 10 patients in the clinical trial Phydelio (EudraCT-No 2008-007237-47).
Time frame: This parameter is measured at the beginning of the investigation
Venous return will be assessed after ICU admission by venous return pressure gradient (dVR)
Claudia Spies
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06363149
Blood Coagulation Disorders, Critical Illness
Lucknow, Uttar Pradesh, India
View Trial DetailsNCT07695337
Infections, Inflammation
Banhā, Qalyubia Governorate, Egypt
View Trial DetailsNCT05824767
Infections, Inflammation
Albuquerque, New Mexico, United States
View Trial DetailsNCT07313670
Infections, Inflammation
Karachi, Sindh, Pakistan
View Trial Details